Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 3/20 | 0.92 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.92 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.92 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | TACR2 | P21452 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091502 | 1.00 | HDAC2 (0.92) | HDAC2HDAC3HDAC1MAOBCCR2 | |
| SCHEMBL3087553 | 0.96 | HDAC2 (1.00) | HDAC2HDAC3HDAC1MAOBCCR2 | |
| SCHEMBL3087551 | 0.96 | HDAC2 (1.00) | HDAC2HDAC3HDAC1MAOBCCR2 | |
| SCHEMBL3098550 | 0.93 | HDAC1 (0.79) | HDAC2HDAC3HDAC1TACR2ALDH1A1 | |
| SCHEMBL3098559 | 0.93 | HDAC1 (0.79) | HDAC2HDAC3HDAC1TACR2ALDH1A1 | |
| SCHEMBL8027039 | 0.92 | HDAC1 (0.77) | HDAC2HDAC3HDAC1ALDH1A1GAA | |
| SCHEMBL3102240 | 0.91 | HDAC2 (0.77) | HDAC2HDAC3HDAC1MAOBCCR2 | |
| SCHEMBL3102216 | 0.91 | HDAC2 (0.77) | HDAC2HDAC3HDAC1MAOBCCR2 | |
| SCHEMBL3090531 | 0.91 | HDAC1 (0.76) | HDAC2HDAC3HDAC1ALDH1A1GAA | |
| SCHEMBL3091521 | 0.91 | HDAC1 (0.76) | HDAC2HDAC3HDAC1CCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238103-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-7795315-B2 | N-(2-amino-phenyl)-amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795315-B2 | N-(2-amino-phenyl)-amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795315-B2 | N-(2-amino-phenyl)-amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| WO-2009095324-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095324-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | MKI67, API5, BAD | HDAC2 973/4885HDAC3 1401/4885HDAC1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.